Access Bio

Access Bio is a New Providence, New Jersey-based global health diagnostics company — a trusted partner in global health whose CareStart™, CareSuperb™, CareGene™, and CareSURE™ product platforms serve healthcare providers, governments, NGOs, and institutional buyers across more than 100 countries with the rapid diagnostic testing, molecular diagnostics, and point-of-care analyzer solutions that make accurate, timely disease detection accessible in the clinical environments where it matters most. Founded and led by a team whose diagnostic product expertise spans malaria, HIV, syphilis, dengue, G6PD deficiency, influenza, COVID-19, HPV, and the full range of infectious disease and chronic condition diagnostics that global health organizations depend on, Access Bio has built a product portfolio whose depth and clinical validation reflect more than two decades of investment in the rapid diagnostic testing technology that serves both the high-resource clinical settings of North America and Europe and the resource-limited environments of sub-Saharan Africa, South and Southeast Asia, and Latin America where reliable point-of-care diagnostics are a genuine public health infrastructure need.

The Access Bio product ecosystem spans four primary categories. The CareStart™ Rapid Diagnostic Tests platform includes the CareStart™ Malaria RDT — one of the most widely distributed and WHO-prequalified malaria rapid tests in the world — alongside rapid tests for dengue, G6PD deficiency, HIV, syphilis, and the CareStart™ Flu A&B Plus rapid influenza diagnostic. The COVID-19 Detection Kits platform includes the CareStart™ COVID-19 Antigen Home Test and combination COVID-19/Flu detection solutions. The CareSURE™ Analyzer platform delivers quantitative point-of-care results for HbA1c, albumin-to-creatinine ratio, and C-reactive protein through a portable, clinic-ready analyzer system. The CareGene™ Molecular Diagnostics platform extends Access Bio's diagnostic reach into HPV screening, STD detection, and arboviral disease genotyping through real-time PCR kits whose clinical sensitivity and specificity meet the standards of the laboratory-based molecular testing they are designed to replace or supplement in the point-of-care and resource-limited settings where Access Bio's distribution infrastructure operates.

The product explainer video produced by VID for Access Bio was built to communicate the specific product value, clinical application, and ease-of-use that Access Bio's diagnostic products deliver to the healthcare provider, institutional buyer, distribution partner, and public health organization evaluating rapid diagnostic testing solutions. The clinical and institutional buyer audience that Access Bio reaches — hospital purchasing managers, public health ministry officials, NGO procurement teams, and the clinical staff whose daily work the products serve — makes product adoption decisions through a combination of regulatory validation data, clinical performance evidence, and the practical understanding of how the product integrates into existing clinical workflows. The explainer video addresses the practical dimension of that evaluation — communicating how Access Bio's products work, why their design and performance make them the right solution for the specific clinical contexts they serve, and what the experience of using them in a real diagnostic workflow looks and feels like.

The half-day on-site production methodology gave VID's team the direct access to Access Bio's product, environment, and team that a clinical diagnostic product explainer requires — the product close-up footage, the use-case demonstration, and the organizational context that makes the finished video feel grounded in the specific reality of Access Bio's products rather than the generic product marketing aesthetic that clinical audiences have learned to discount. Post-production editing delivered the polished, distribution-ready asset optimized for website deployment, sales enablement distribution, and the trade show, conference, and institutional sales contexts where Access Bio reaches its buyer audience.

Access Bio needed a professionally produced product explainer video that could communicate the clinical value, ease of use, and global health mission of its rapid diagnostic testing platform to a sophisticated institutional buyer audience evaluating diagnostic testing solutions. The challenge was not the product's clinical credibility — Access Bio's CareStart™ platform is WHO-prequalified and distributed in more than 100 countries. The challenge was translating that clinical and operational depth into a compelling, accessible video asset that communicates the product's specific value in the compressed format that a buyer evaluation, a trade conference, or a website visit allows.

VID produced the Access Bio product explainer through a half-day on-site production and full post-production engagement — capturing the product demonstrations, use-case context, and brand environment that give the explainer video its specific clinical authenticity. The production approach was calibrated to the institutional buyer audience's communication register — the visual quality and editorial precision that communicates Access Bio's product seriousness and clinical credibility without the overwrought production style that makes healthcare marketing content feel disconnected from the real-world clinical environments it is meant to serve.

Product explainer video delivered and deployed across Access Bio's website, sales enablement infrastructure, and distribution partner communications — giving the global health diagnostics company a permanent, professionally produced video asset that communicates CareStart™ and Access Bio product value to healthcare providers, institutional buyers, and distribution partners across the more than 100 countries where Access Bio's diagnostic platforms serve clinical and public health needs.

Access Bio's product explainer video runs as a permanent sales enablement and brand authority asset across the company's digital presence — website, trade show and conference distribution, and institutional sales conversations — communicating the diagnostic product value that converts a clinical buyer's initial evaluation into a procurement relationship.